Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Guided Treatment in DLBCL
NCT04025593Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, lenalidomide, tucidinostat, decitabine in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
ibrutiniblenalidomidetucidinostatdecitabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04025593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025593.